Clinical Trials Logo

Scars clinical trials

View clinical trials related to Scars.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06202274 Recruiting - Acne Clinical Trials

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

Start date: October 4, 2023
Phase: N/A
Study type: Interventional

This is a non-randomized, multi-center, open-label, prospective clinical study evaluating the clinical treatment with Candela Medical Technology.

NCT ID: NCT06122090 Recruiting - Cicatrix Clinical Trials

Treatment of Hypopigmented Scars With Bimatoprost

Start date: July 18, 2023
Phase: Phase 2
Study type: Interventional

Patients who have hypo-pigmented burn scar will have two scars chosen and randomized to treated scar and control scar. The subject will then have both scars treated with fractional ablative CO2 laser (FLSR). The treated scar will have bimatoprost delivered through the laser channels, while the control will have the vehicle (normal saline) only delivered. The treatment will continue for 14 days with twice daily application. The scars will then be monitored at a 2-week follow-up visit where levels of melanin will be evaluated. Tissue punch biopsies will also be used to evaluate the mechanism of action of bimatoprost. Treatment will occur for 6 sessions at 4-6 week intervals including follow- up visits and evaluations.

NCT ID: NCT06021275 Recruiting - Scars Clinical Trials

Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.

NCT ID: NCT05847530 Recruiting - Skin Laxity Clinical Trials

Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions

Start date: May 2024
Phase: N/A
Study type: Interventional

The primary objective of this pilot study is exploratory investigation evaluating the Potenza microneedle fractional radiofrequency (RF) device and may be used in combination with the Icon intense pulsed light (IPL) device.

NCT ID: NCT05528328 Recruiting - Scars Clinical Trials

Post-surgical Scars After the Use of CACIPLIQ20

MATRISCAR
Start date: March 21, 2023
Phase: Phase 3
Study type: Interventional

Following surgical procedures or injury, cutaneous scars can develop due to production of collagen-rich connective tissue. These scars may be accompanied by redness, itching, pain, and restricted mobility of the skin. Typically, after a few weeks, the scar matures, becoming lighter and narrower, although full maturation of a scar may take up to 2 years. In some cases, however, cutaneous scars can be unsightly or can even become hyper- trophic or result in keloids. Preventing pathological scarring is much easier than treating scars later and should be started as early as possible after the injury or surgery. CACIPLIQ20® is a medical device used for the treatment of chronic skin ulcers, and contains a molecule belonging to the family of ReGeneraTing Agents (RGTA®). RGTA®s are biodegradable polymers that mimic the action of heparan sulfates found in the extracellular matrix of injured tissues. RGTA® accelerates tissue healing in various animal models, by stabilizing and protecting heparin-binding growth factors (HBGFs) and matrix proteins. In addition to its effects on hard-to-heal chronic wounds, CACIPLIQ20® was found to improve acute wound healing in pre-clinical models and in several case reports and controlled clinical studies. A first open label-controlled study showed that the topical application of RGTA® improved skin healing in mammoplasty patients and notably reduced oedema and pain in patients who had undergone centrofacial lift surgery compared to untreated patients. Results from this first study were confirmed in a double-blind placebo self-controlled trial conducted in two medical institutions in China involving 71 patients. The Chinese study showed that a single application of CACIPLIQ20® significantly improved scar healing quality at 14 days as well as scar symptoms including pain, swelling and exudate. The aim of the MATRISCAR study is to confirm the previous results in a double-blind, placebo-controlled randomized clinical trial.

NCT ID: NCT03782038 Recruiting - Scars Clinical Trials

Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars

Start date: September 13, 2018
Phase: N/A
Study type: Interventional

A study to evaluate the safety and effectiveness of a micro coring device for the treatment of scars.

NCT ID: NCT02195063 Recruiting - Pain Clinical Trials

Survey Study for Pain Management, Wound Care, Scar Care or UDT

Start date: November 2013
Phase: Phase 4
Study type: Observational

This is a survey study that will be given to patients who have been prescribed a topical compound for pain management, wound care or scar care or to patients who have been requested to do a urinary drug test (UDT) by their provider. The initial survey for pain management, wound care, scar care or UDT will be given to the patient by their providers during their office visit.